Why is Rafael stock crashing today?

Rafael Holdings Inc stock experienced a dramatic -36.0% decline in afternoon trading following Cyclo Therapeutics' announcement that its Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C failed to meet statistical significance on its primary endpoint. The disappointing results, disclosed in a press release and investor conference call, saw shares drop sharply at the opening bell.

While a prespecified analysis of patients on background miglustat and/or leucine therapy showed statistical significance, reflecting a 71% reduction in disease progression compared to placebo, the overall primary endpoint miss left investors disappointed. Rafael had planned to submit a New Drug Application to the FDA in Q4 2026; however, the partial efficacy results did not meet the expectations of investors who were anticipating a clean primary endpoint win.

Trading volume surged to over 12 times the stock's 100-day average, leaving the stock trading as low as $1.20 intraday, well below its 52-week high of $3.96. The company maintains that it remains on track for an FDA submission, but the partial nature of the trial results proved disheartening for those relying on this de-risking event.

With no broader market stress to offset the company-specific decline, Rafael's stock suffered one of its steepest single-session drops, unaffected by broader market gains in U.S. equity indices.